Serglycin in Health and Diseases

Anatomical Record

Volumn 295, Issue 9, 2012, Pages 1415-1420

  Scully, Olivia J ^a   Chua, Pei Jou ^a   Harve, Karthik S ^a   Bay, Boon Huat ^a   Yip, George W ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cancer; Hemostasis; Immunity; Inflammatory diseases; Platelet disorders; Proteoglycan; Reproduction; Serglycin

Indexed keywords

PROTEOGLYCAN; SERGLYCIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; APOPTOSIS; ATHEROSCLEROSIS; CELL GROWTH; CELLULAR IMMUNITY; GENE EXPRESSION; HEMOSTASIS; HUMAN; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; REPRODUCTION; REVIEW; THROMBOSIS;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; CELL ENLARGEMENT; HEMOSTASIS; HUMANS; INFLAMMATION MEDIATORS; NEOPLASMS; PROTEOGLYCANS; REPRODUCTION; VESICULAR TRANSPORT PROTEINS;

EID: 84865294850     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22536     Document Type: Review

References (77)

1. Abrink M, Grujic M, Pejler G. 2004. Serglycin is essential for maturation of mast cell secretory granule. J Biol Chem 279: 40897-40905.
2. Badovinac VP, Porter BB, Harty JT. 2002. Programmed contraction of CD8(+) T cells after infection. Nat Immunol 3: 619-626.
3. Bechara C, Wang X, Chai H, Lin PH, Yao Q, Chen C. 2007. Growth-related oncogene-alpha induces endothelial dysfunction through oxidative stress and downregulation of eNOS in porcine coronary arteries. Am J Physiol Heart Circ Physiol 293: H3088-H3095.
4. Beyer-Sehlmeyer G, Hiddemann W, Wormann B, Bertram J. 1999. Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin. Eur J Cancer 35: 1735-1742.
5. Biederbick A, Licht A, Kleene R. 2003. Serglycin proteoglycan is sorted into zymogen granules of rat pancreatic acinar cells. Eur J Cell Biol 82: 19-29.
6. Bourdon MA, Oldberg A, Pierschbacher M, Ruoslahti E. 1985. Molecular cloning and sequence analysis of a chondroitin sulfate proteoglycan cDNA. Proc Natl Acad Sci USA 82: 1321-1325.
7. Braga T, Grujic M, Lukinius A, Hellman L, Abrink M, Pejler G. 2007. Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. Biochem J 403: 49-57.
8. Breland UM, Halvorsen B, Hol J, Oie E, Paulsson-Berne G, Yndestad A, Smith C, Otterdal K, Hedin U, Waehre T, Sandberg WJ, Froland SS, Haraldsen G, Gullestad L, Damas JK, Hansson GK, Aukrust P. 2008. A potential role of the CXC chemokine GROalpha in atherosclerosis and plaque destabilization: downregulatory effects of statins. Arterioscler Thromb Vasc Biol 28: 1005-1011.
9. Castronuevo P, Thornton MA, McCarthy LE, Klimas J, Schick BP. 2003. DNase I hypersensitivity patterns of the serglycin proteoglycan gene in resting and phorbol 12-myristate 13-acetate-stimulated human erythroleukemia (HEL), CHRF 288-11, and HL-60 cells compared with neutrophils and human umbilical vein endothelial cells. J Biol Chem 278: 48704-48712.
10. Cockerill PN. 2000. Identification of DNaseI hypersensitive sites within nuclei. Methods Mol Biol 130: 29-46.
11. Cuenca RE, Azizkhan RG, Haskill S. 1992. Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol 1: 323-329.
12. Deininger PL, Batzer MA. 1999. Alu repeats and human disease. Mol Genet Metab 67: 183-193.
13. Donehower LA, Slagle BL, Wilde M, Darlington G, Butel JS. 1989. Identification of a conserved sequence in the non-coding regions of many human genes. Nucleic Acids Res 17: 699-710.
14. Duelli A, Rönnberg E, Waern I, Ringvall M, Kolset SO, Pejler G. 2009. Mast cell differentiation and activation is closely linked to expression of genes coding for the serglycin proteoglycan core protein and a distinct set of chondroitin sulfate and heparin sulfotransferases. J Immunol 183: 7073-7083.
15. Eisman R, Surrey S, Ramachandran B, Schwartz E, Poncz M. 1990. Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood 76: 336-344.
16. Elliott JF, Miller CL, Pohajdak B, Talbot D, Helgason CD, Bleackley RC, Paetkau V. 1993. Induction of a proteoglycan core protein mRNA in mouse T lymphocytes. Mol Immunol 30: 749-754.
17. Grujic M, Braga T, Lukinius A, Eloranta ML, Knight SD, Pejler G, Abrink M. 2005. Serglycin-deficient cytotoxic T lymphocytes display defective secretory granule maturation and granzyme B storage. J Biol Chem 280: 33411-33418.
18. Grujic M, Christensen JP, Sorensen MR, Abrink M, Pejler G, Thomsen AR. 2008. Delayed contraction of the CD8+ T cell response toward lymphocytic choriomeningitis virus infection in mice lacking serglycin. J Immunol 181: 1043-1051.
19. Guckel B, Berek C, Lutz M, Altevogt P, Schirrmacher V, Kyewski BA. 1991. Anti-CD2 antibodies induce T cell unresponsiveness in vivo. J Exp Med 174: 957-967.
20. Heldin CH. 1992. Structural and functional studies on platelet-derived growth factor. EMBO J 11: 4251-4259.
21. Henningsson F, Hergeth S, Cortelius R, Abrink M, Pejler G. 2006. A role for serglycin proteoglycan in granular retention and processing of mast cell secretory granule components. FEBS J 273: 4901-4912.
22. Hoffmann JC, Herklotz C, Zeidler H, Bayer B, Westermann J. 1997. Anti-CD2 (OX34) MoAb treatment of adjuvant arthritic rats: attenuation of established arthritis, selective depletion of CD4+ T cells, and CD2 down-modulation. Clin Exp Immunol 110: 63-71.
23. Humphries DE, Nicodemus CF, Schiller V, Stevens RL. 1992. The human serglycin gene. Nucleotide sequence and methylation pattern in human promyelocytic leukemia HL-60 cells and T-lymphoblast Molt-4 cells. J Biol Chem 267: 13558-13563.
24. Jackson CW, Hutson NK, Steward SA, Saito N, Cramer EM. 1991. Platelets of the Wistar Furth rat have reduced levels of alpha-granule proteins. An animal model resembling gray platelet syndrome. J Clin Invest 87: 1985-1991.
25. Kaplan KL, Owen J. 1981. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57: 199-202.
26. Keith Ho HC, McGrath KE, Brodbeck KC, Palis J, Schick BP. 2001. Serglycin proteoglycan synthesis in the murine uterine decidua and early embryo. Biol Reprod 64: 1667-1676.
27. Kim JS, Werth VP. 2011. Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem 59: 780-790.
28. Kitaya K, Yamaguchi T, Yasuo T, Okubo T, Honjo H. 2007. Post-ovulatory rise of endometrial CD16(-) natural killer cells: in situ proliferation of residual cells or selective recruitment from circulating peripheral blood? J Reprod Immunol 76: 45-53.
29. Kole LB, Haynes SR, Jelinek WR. 1983. Discrete and heterogeneous high molecular weight RNAs complementary to a long dispersed repeat family (a possible transposon) of human DNA. J Mol Biol 165: 257-286.
30. Kolset SO, Pejler G. 2011. Serglycin: a structural and functional chameleon with wide impact on immune cells. J Immunol 187: 4927-4933.
31. Kolset SO, Tveit H. 2008. Serglycin-structure and biology. Cell Mol Life Sci 65: 1073-1085.
32. Kolset SO, Zernichow L. 2008. Serglycin and secretion in human monocytes. Glycoconj J 25: 305-311.
33. Korkmaz B, Moreau T, Gauthier F. 2008. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 90: 227-242.
34. Kulseth MA, Mustorp SL, Uhlin-Hansen L, Öberg F, Kolset SO. 1998. Serglycin expression during monocytic differentiation of U937-1 cells. Glycobiology 8: 747-753.
35. Li X, Bradford BU, Dalldorf F, Goyert SM, Stimpson SA, Thurman RG, Makarov SS. 2004. CD14 mediates the innate immune responses to arthritopathogenic peptidoglycan-polysaccharide complexes of Gram-positive bacterial cell walls. Arthritis Res Ther 6: R273-R281.
36. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D, Qin L, Bao YN, Zheng FJ, Chia CS, Iyer NG, Kang TB, Zeng YX, Soo KC, Trent JM, Teh BT, Qian CN. 2011. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71: 3162-3172.
37. Li XJ, Qian CN. 2011. Serglycin in human cancers. Chin J Cancer 30: 585-589.
38. Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. 2003. Granzyme B: a natural born killer. Immunol Rev 193: 31-38.
39. Maillet P, Alliel PM, Mitjavila MT, Perin JP, Jolles P, Bonnet F. 1992. Expression of the serglycin gene in human leukemic cell lines. Leukemia 6: 1143-1147.
40. Mattei MG, Périn JP, Alliel PM, Bonnet F, Maillet P, Passage E, Mattei JF, Jollès P. 1989. Localization of human platelet proteoglycan gene to chromosome 10, band q22.1, by in situ hybridization. Hum Genet 82: 87-88.
41. Meen AJ, Øynebråten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, Kolset SO. 2011. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J Biol Chem 286: 2636-2647.
42. Melo FR, Lundequist A, Calounova G, Wernersson S, Pejler G. 2011a. Lysosomal membrane permeabilization induces cell death in human mast cells. Scand J Immunol 74: 354-362.
43. Melo FR, Waern I, Rönnberg E, Åbrink M, Lee DM, Schlenner SM, Feyerabend TB, Rodewald HR, Turk B, Wernersson S, Pejler G. 2011b. A role for serglycin proteoglycan in mast cell apoptosis induced by a secretory granule-mediated pathway. J Biol Chem 286: 5423-5433.
44. Nicodemus CF, Avraham S, Austen KF, Purdy S, Jablonski J, Stevens RL. 1990. Characterization of the human gene that encodes the peptide core of secretory granule proteoglycans in promyelocytic leukemia HL-60 cells and analysis of the translated product. J Biol Chem 265: 5889-5896.
45. Niemann CU, Abrink M, Pejler G, Fischer RL, Christensen EI, Knight SD, Borregaard N. 2007a. Neutrophil elastase depends on serglycin proteoglycan for localization in granules. Blood 109: 4478-4486.
46. Niemann CU, Cowland JB, Klausen P, Askaa J, Calafat J, Borregaard N. 2004. Localization of serglycin in human neutrophil granulocytes and their precursors. J Leukoc Biol 76: 406-415.
47. Niemann CU, Kjeldsen L, Ralfkiaer E, Jensen MK, Borregaard N. 2007b. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21: 2406-2410.
48. Nurden AT, Nurden P. 2007. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 21: 21-36.
49. Oldberg A, Hayman EG, Ruoslahti E. 1981. Isolation of a chondroitin sulfate proteoglycan from a rat yolk sac tumor and immunochemical demonstration of its cell surface localization. J Biol Chem 256: 10847-10852.
50. Omtvedt LA, Kolset SO, Thoen J, Forre Y, Gill MR. 2001. Serglycin expression in CD2+ and CD14+ cells from patients with various rheumatic diseases. Scand J Rheumatol 30: 164-166.
51. Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, Khalapyan TZ, Wolfe ML, Fairman R, Mitchell M, Carpenter J, Golden MA, Cines DB, Sachais BS. 2003. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 90: 1112-1120.
52. Ringvall M, Rönnberg E, Wernersson S, Duelli A, Henningsson F, Abrink M, García-Faroldi G, Fajardo I, Pejler G. 2008. Serotonin and histamine storage in mast cell secretory granules is dependent on serglycin proteoglycan. J Allergy Clin Immunol 121: 1020-1026.
53. Rodeberg DA, Morris RE, Babcock GF. 1997. Azurophilic granules of human neutrophils contain CD14. Infect Immun 65: 4747-4753.
54. Sachais BS, Turrentine T, Dawicki McKenna JM, Rux AH, Rader D, Kowalska MA. 2007. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost 98: 1108-1113.
55. Santoni A, Carlino C, Stabile H, Gismondi A. 2008. Mechanisms underlying recruitment and accumulation of decidual NK cells in uterus during pregnancy. Am J Reprod Immunol 59: 417-424.
56. Schick BP. 2010. Serglycin proteoglycan deletion in mouse platelets: physiological effects and their implications for platelet contributions to thrombosis, inflammation, atherosclerosis, and metastasis. Prog Mol Biol Transl Sci 93: 235-287.
57. Schick BP, Gradowski JF, San Antonio JD. 2001a. Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97: 449-458.
58. Schick BP, Ho HC, Brodbeck KC, Wrigley CW, Klimas J. 2003. Serglycin proteoglycan expression and synthesis in embryonic stem cells. Biochim Biophys Acta 1593: 259-267.
59. Schick BP, Jacoby JA. 1995. Serglycin and betaglycan proteoglycans are expressed in the megakaryocytic cell line CHRF 288-11 and normal human megakaryocytes. J Cell Physiol 165: 96-106.
60. Schick BP, Pestina TI, San Antonio JD, Stenberg PE, Jackson CW. 1997. Decreased serglycin proteoglycan size is associated with the platelet alpha granule storage defect in Wistar Furth hereditary macrothrombocytopenic rats. Serglycin binding affinity to type I collagen is unaltered. J Cell Physiol 172: 87-93.
61. Schick BP, Petrushina I, Brodbeck KC, Castronuevo P. 2001b. Promoter regulatory elements and DNase I-hypersensitive sites involved in serglycin proteoglycan gene expression in human erythroleukemia, CHRF 288-11, and HL-60 cells. J Biol Chem 276: 24726-24735.
62. Skliris A, Happonen KE, Terpos E, Labropoulou V, Børset M, Heinegård D, Blom AM, Theocharis AD. 2011. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma. Eur J Immunol 41: 437-449.
63. Stellrecht CM, Mars WM, Miwa H, Beran M, Saunders GF. 1991. Expression pattern of a hematopoietic proteoglycan core protein gene during human hematopoiesis. Differentiation 48: 127-135.
64. Stevens RL, Avraham S, Gartner MC, Bruns GA, Austen KF, Weis JH. 1988. Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. J Biol Chem 263: 7287-7291.
65. Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A, Hjerpe A. 2006. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281: 35116-35128.
66. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. 2010. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. The FEBS J 277: 3904-3923.
67. Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F, Yagita H, Suzuki K, Miyasaka M. 1995. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem 270: 7437-7444.
68. Uhlin-Hansen L, Eskeland T, Kolset SO. 1989. Modulation of the expression of chondroitin sulfate proteoglycan in stimulated human monocytes. J Biol Chem 264: 14916-14922.
69. Uhlin-Hansen L, Wik T, Kjellen L, Berg E, Forsdahl F, Kolset SO. 1993. Proteoglycan metabolism in normal and inflammatory human macrophages. Blood 82: 2880-2889.
70. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME. 2008. Essentials of glycobiology. 2nd ed. New York: Cold Spring Harbor Laboratory Press.
71. Werth BB, Bashir M, Chang L, Werth VP. 2011. Ultraviolet irradiation induces the accumulation of chondroitin sulfate, but not other glycosaminoglycans, in human skin. PloS One 6: e14830.
72. White JG. 2004. Medich giant platelet disorder: a unique alpha granule deficiency I. Structural abnormalities. Platelets 15: 345-353.
73. Wong ET, Jenne DE, Zimmer M, Porter SD, Gilks CB. 1999. Changes in chromatin organization at the neutrophil elastase locus associated with myeloid cell differentiation. Blood 94: 3730-3736.
74. Woulfe DS, Lilliendahl JK, August S, Rauova L, Kowalska MA, Abrink M, Pejler G, White JG, Schick BP. 2008. Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice. Blood 111: 3458-3467.
75. Yasuo T, Kitaya K, Yamaguchi T, Fushiki S, Honjo H. 2008. Possible role of hematopoietic CD44/chondroitin sulfate interaction in extravasation of peripheral blood CD16(-) natural killer cells into human endometrium. J Reprod Immunol 78: 1-10.
76. Yip GW, Smollich M, Gotte M. 2006. Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5: 2139-2148.
77. Zernichow L, Abrink M, Hallgren J, Grujic M, Pejler G, Kolset SO. 2006. Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J Biol Chem 281: 26792-26801.